Warren , R., A. Armstrong, M. Gooderham, B. Strober, D. Thaci, S. Imafuku, H. Sofen, L. Spelman, N. Korman, M. Zheng, E. Colston, J. Throup, S. Kundu, R. Kisa, S. Banerjee, and A. . Blauvelt. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 2, Mar. 2022, p. s4, doi:10.25251/skin.6.supp.4.